avutometinib,defactinib
verastem oncology
['defactinib', 'avutometinib', 'ramp 201']
patients with recurrent #lgsoc had high responses with #avutometinib + #defactinib vs avutometinib monotherapy, according to data from the ramp 201 trial. #asco2023 | 
Oncology news and insights from leading researchers and cancer centers.